A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Summary

The primary purpose of this study is to evaluate the safety and tolerability of ASP0367. This study will also evaluate the pharmacokinetics, pharmacodynamics and efficacy on muscle function of ASP0367.

Timeline

Start

2021-02-24

Primary completion

2022-09-04

Completion

2022-09-04

Outcome

Outcome not reported

Stopped: “Operational Reasons”

Drugs

Indications